Lithiated gold nanoparticles as promising therapy for Alzheimer's disease
Alzheimer's & Dementia · 2025-12 · 21 (S5)
DOI: 10.1002/alz70859_097598 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 25.12.2025. Verfasst von Gulia Puliatti und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Glycogen Synthase Kinase 3β (GSK‐3β), is a hub kinase whose activity deregulation is involved in mood disorders and neurodegenerative diseases, including Alzheimer's disease (AD). Many efforts have been made to develop drugs able to modulate this kinase, but most of them did not reach the human use. The lithium cation (Li+) is a potent GSK‐3 inhibitor, that modulates kinase activity by inducing its phosphorylation at Ser9 (pGSK‐3β‐S9). Unfortunately, Li+ faces challenges in systemic use due to its toxicity, especially for kidneys and thyroid. Nowadays, lithium salts, taken orally, are used for treating neuropsychiatric disorders, but safe doses are ineffective against other GSK‐3‐dependent illnesses, which require higher, toxic doses. Thereby, identifying novel lithium administration routes reaching the target organ(s) (e.g., the brain) bypassing the systemic administration and without damaging other organs, would be desirable.
Method
We developed a tool consisting of gold nanoparticles (AuNPs) functionalized with glutathione and charged with Li+ in the outer corona, forming aggregates in water of 250 nm in diameter (a‐LiG‐AuNPs). a‐LiG‐AuNPs internalize cells and determine an efficient intracellular release of Li+. The effects of a‐LiG‐AuNPs in modulating GSK‐3β and contrasting AD neuropathological signs have been tested on cultured cells and in mice.
Result
Addition of a‐LiG‐AuNPs to the culture medium of SH‐SY5Y cells induced a significant increase of pGSK‐3β‐S9 respect to classical salt formulations, even at low Li+ concentration (0.15 mM) normally resulting ineffective with lithium salts. If administered intranasally in healthy mice (C57BL/6; 5 days a week, twice a month, up to 5 months), a‐LiG‐AuNPs directly reached the brain and increased pGSK‐3β‐S9 in situ (+130%; p
Zitieren
APA
Puliatti, G., Cannata, B., Sposito, L., Albini, M., Grassi, A., Buonerba, A., Grassi, C., & Piacentini, R. (2025). Lithiated gold nanoparticles as promising therapy for Alzheimer's disease. Alzheimer's & Dementia, 21(S5). https://doi.org/10.1002/alz70859_097598
Vancouver
Puliatti G, Cannata B, Sposito L, Albini M, Grassi A, Buonerba A, et al. Lithiated gold nanoparticles as promising therapy for Alzheimer's disease. Alzheimer's & Dementia. 2025;21(S5). doi:10.1002/alz70859_097598
BibTeX
@article{Puliatti2025,
author = {Puliatti, Gulia and Cannata, Beatrice and Sposito, Laura and Albini, Martina and Grassi, Alfonso and Buonerba, Antonio and Grassi, Claudio and Piacentini, Roberto},
title = {Lithiated gold nanoparticles as promising therapy for Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {S5},
doi = {10.1002/alz70859_097598}
}
EUVIMED